Drug Profile

IVX 037

Alternative Names: IVX-037

Latest Information Update: 01 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ImmVirX
Class Antineoplastics; Immunotherapies; Oncolytic viruses
Mechanism of Action Cell death stimulants; Immunologic cytotoxicity

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Solid tumours

Most Recent Events

25 Apr 2025 Preclinical trials in Solid tumours in Australia (IV), prior to April 2025
25 Apr 2025 Pharmacodynamics and adverse events data from the preclinical studies in Solid tumours presented at the 116^th Annual Meeting of the American Association for Cancer Research (AACR-2025)
06 Sep 2024 ImmVirx announces intention to submit IND to US FDA for Solid tumours in the US, in 2024 ((ImmVirx pipeline, September 2024)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com